Azitra (AZTR) Current Deferred Revenue (2022 - 2023)
Azitra (AZTR) reported Current Deferred Revenue of $310700.0 for Q2 2023, up 99.17% quarter-over-quarter from $156000.0 in Q4 2022.
Azitra (AZTR) Current Deferred Revenue (2022 - 2023) Analysis & Trends
Azitra has reported Current Deferred Revenue for 2 years, with the latest figure at $310700.0 in Q2 2023.
- For the quarter ending Q2 2023, Current Deferred Revenue changed N/A year-over-year to $310700.0; the trailing twelve-month figure through Jun 2023 stood at $310700.0 (changed N/A YoY), and the FY2022 full-year result was $156000.0, changed N/A from the prior year.
- Current Deferred Revenue for Q2 2023 stood at $310700.0, up from $156000.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $310700.0 in Q2 2023, with the low at $156000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Azitra | 20,900.00 | 20,900.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 310,700.00 |
| Dec 31, 2022 | 156,000.00 |